CYP2C19 Genotyping in Anticoagulated Patients After Percutaneous Coronary Intervention: Should It Be Routine?

Circulation. 2022 Mar 8;145(10):721-723. doi: 10.1161/CIRCULATIONAHA.121.057028. Epub 2022 Mar 7.

Dimitri J Maamari^{1

2}, Farouc A Jaffer^{3

4

5}, Amit V Khera^{1

3

5

2}, Akl C Fahed^{1

3

4

5

2}

¹ Center for Genomic Medicine (D.J.M., A.V.K., A.C.F.), Massachusetts General Hospital.
² Cardiovascular Disease Initiative, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge (D.J.M., A.V.K., A.C.F.).
³ Division of Cardiology (F.A.J., A.V.K., A.C.F.), Department of Medicine, Massachusetts General Hospital.
⁴ Cardiovascular Research Center, Cardiology Division (F.A.J., A.C.F.), Massachusetts General Hospital.
⁵ Department of Medicine, Harvard Medical School (F.A.J., A.V.K., A.C.F.) Boston.

No abstract available

Keywords: anticoagulants; cytochrome P-450 CYP2C19; pharmacogenetics; precision medicine.

Publication types